Core Viewpoint - Anxu Bio (688075.SH) reported its Q3 2025 results, highlighting a significant presence of institutional investors holding 39.66% of its total shares, with a slight decrease in institutional ownership compared to the previous quarter [1] Institutional Investors - As of October 30, 2025, five institutional investors disclosed holdings in Anxu Bio, totaling 50.3993 million shares, which represents 39.66% of the company's total share capital [1] - The institutional ownership decreased by 0.19 percentage points compared to the previous quarter [1] Public Funds - Two public funds increased their holdings during this period, namely Guangfa Value Core Mixed A and Xinyuan Specialized and New Mixed A, with an increase in holdings accounting for 0.44% [1] - A total of 46 public funds did not disclose their holdings this quarter, including notable funds such as Bosera Phoenix Leading Mixed A and Morgan Stanley Multi-Factor Strategy Mixed [1]

Core Points - The company assures that the quarterly report is true, accurate, and complete, with no false records or significant omissions [2][3] - The financial statements for the third quarter are unaudited [3][5] - The company has not identified any non-recurring gains or losses during the reporting period [3][4] Financial Data Summary - The financial data is presented in RMB, with the reporting period defined as the three months from the beginning to the end of the quarter [3] - The company has not reported any changes in major accounting data or financial indicators [4][5] - The company has not executed any new accounting standards or interpretations affecting the financial statements for the current year [6] Shareholder Information - There are no changes reported in the top ten shareholders or any significant shareholder activities during the reporting period [4] Other Important Information - The company has not identified any additional important information regarding its operational performance during the reporting period [5] - The financial statements include the consolidated balance sheet and cash flow statement for the first nine months of 2025, both of which are unaudited [5][6]

Core Insights - Anxu Bio, established in July 2008 and listed on the Shanghai Stock Exchange in November 2021, is a leading company in the domestic POCT reagent field, with a full industry chain advantage and high product quality and technology level [1] Financial Performance - For Q3 2025, Anxu Bio reported revenue of 325 million yuan, ranking 21st out of 39 in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan and the second competitor's 3.127 billion yuan, as well as below the industry average of 708 million yuan and median of 330 million yuan [2] - The company's net profit for the same period was 64.31 million yuan, ranking 14th in the industry, again far below the top competitor's net profit of 1.588 billion yuan and the second competitor's 1.205 billion yuan, but higher than the industry median of 26.19 million yuan and lower than the industry average of 110 million yuan [2] Financial Ratios - Anxu Bio's debt-to-asset ratio for Q3 2025 was 8.59%, down from 11.21% in the previous year and below the industry average of 18.29%, indicating strong solvency [3] - The gross profit margin for the same period was 40.82%, a decrease from 42.11% year-on-year and lower than the industry average of 56.20%, suggesting a need for improvement in profitability [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 1.10% to 6,090, while the average number of circulating A-shares held per shareholder decreased by 1.08% to 20,900 [5] - Among the top ten circulating shareholders, Guangfa Value Core Mixed A ranked fifth with 3.5645 million shares, an increase of 549,800 shares from the previous period, while the eighth largest shareholder,招商景气优选股票A, held 600,000 shares, unchanged from the previous period [5]

证券代码：688075 证券简称：安旭生物 公告编号：2025-030 杭州安旭生物科技股份有限公司 关于继续使用超募资金及部分闲置募集资金 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理种类：安全性高、流动性好、期限不超过 12 个月（含）的 投资产品（包括但不限于协定性存款、结构性存款、定期存款、通知存款、大 额存单等） 现金管理金额：最高金额不超过人民币 4.5 亿元（含 4.5 亿元），在上 述额度内，资金可以滚动使用。 已履行及拟履行的审议程序：杭州安旭生物科技股份有限公司（以下 简称"公司"或"安旭生物"）于 2025 年 10 月 29 日召开第三届董事会第二次会 议，审议通过了《关于继续使用超募资金及部分闲置募集资金进行现金管理 的议案》，本事项无需提交公司股东会审议。公司保荐机构国联民生证券承销 保荐有限公司对上述事项出具了明确同意的核查意见。 特别风险提示：公司拟开展现金管理的产品属于安全性高、流动性好、 风险低的投资品种，但不排除该项投资受到市场风险、政策风险 ...

国联民生证券承销保荐有限公司 关于杭州安旭生物科技股份有限公司 继续使用超募资金及部分闲置募集资金进行现金管理 一、募集资金基本情况 根据中国证券监督管理委员会于 2021 年 9 月 28 日出具的《关于同意杭州安 旭生物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3138 号），公司获准向社会公开发行人民币普通股 15,333,400 股，每股发行价格为人民 币 78.28 元，募集资金总额为 120,029.86 万元；扣除承销及保荐费用、发行登记 费以及其他交易费用共计 14,445.23 万元（不含增值税金额）后，募集资金净额为 105,584.63 万元，上述资金已全部到位，经信永中和会计师事务所（特殊普通合 伙）审验并于 2021 年 11 月 12 日出具了"XYZH/2021HZAA10537"《验资报告》。 募集资金到账后，已全部存放于经公司董事会批准开设的募集资金专项账户内， 公司与保荐机构、存放募集资金的商业银行签署了募集资金三方监管协议。 二、募集资金投资项目情况 公司本次进行现金管理的资金来源为部分超募资金及部分闲置募集资金，具体 情况如下： | 发行名称 | ...

Financial Performance - The company's revenue for the third quarter was ¥95,539,646.52, a decrease of 38.41% compared to the same period last year[4] - Total profit for the quarter was ¥2,745,852.23, down 86.30% year-over-year[4] - Net profit attributable to shareholders was ¥5,052,702.96, reflecting a decline of 75.31% compared to the previous year[4] - The basic earnings per share for the quarter was ¥0.04, a decrease of 75.00% year-over-year[4] - Net profit for the first three quarters of 2025 was CNY 64,308,065.31, down 52.7% from CNY 135,748,290.64 in the same period of 2024[19] - Basic and diluted earnings per share for the first three quarters of 2025 were both CNY 0.51, compared to CNY 1.07 in the same period of 2024[20] - The company’s total comprehensive income for the first three quarters of 2025 was CNY 60,620,699.74, down from CNY 143,387,343.88 in the same period of 2024[19] Cash Flow and Assets - The company reported a net cash flow from operating activities of ¥1,182,438.02, a significant drop of 95.13% year-to-date[4] - Cash and cash equivalents decreased to RMB 196,861,400.08 from RMB 467,922,697.94, representing a decline of approximately 58%[15] - Total current assets were RMB 4,629,730,923.04, down from RMB 4,769,982,927.28, indicating a decrease of about 3%[15] - Cash flow from operating activities generated a net amount of CNY 1,182,438.02, significantly lower than CNY 24,260,942.83 in the first three quarters of 2024[20] - The total cash flow from operating activities was not detailed, but the overall cash and cash equivalents decreased by 276,540,863.67 during the period[21] - Cash and cash equivalents at the end of the period amounted to 181,742,814.48, slightly up from 181,017,444.31 in the previous period[21] Liabilities and Equity - The company reported a total liability of CNY 484,843,392.64, down from CNY 569,523,608.49 in the previous year[17] - Total equity attributable to shareholders decreased to CNY 5,162,604,172.76 from CNY 5,203,599,188.59[17] - Total liabilities included accounts payable of RMB 278,902,535.40, down from RMB 327,672,505.40, a decrease of about 15%[16] - The company reported a significant reduction in employee compensation liabilities, decreasing to RMB 11,374,288.37 from RMB 19,864,855.74, a decline of approximately 43%[16] Operational Costs and Expenses - Research and development expenses totaled ¥16,292,479.86, a decrease of 40.59% compared to the same period last year[5] - Total operating costs increased slightly to CNY 392,903,928.66 from CNY 390,136,270.04, with operating costs specifically decreasing from CNY 233,453,244.12 to CNY 192,489,887.23, a reduction of 17.5%[18] - Other income decreased to CNY 5,594,830.22 from CNY 14,581,342.75, indicating a decline in additional revenue sources[18] Shareholder Information - The company has no pledged or frozen shares among its top shareholders, indicating a stable ownership structure[12] - The largest shareholder, Hangzhou Aixi Holdings, holds 26.87% of the shares, while the second-largest shareholder, Ling Shisheng, holds 25.12%[12] - The company has not reported any significant changes in shareholder relationships or actions regarding stock lending[13] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect future financial reporting[22] - The company attributed the decline in performance primarily to the impact of U.S. tariffs causing customers to delay orders and foreign exchange losses[9]

证券代码：688075 证券简称：安旭生物 公告编号：2025-029 杭州安旭生物科技股份有限公司 关于产业基金完成注销登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、产业基金情况概述 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"） 于 2022 年 6 月 2 日召开的公司第一届董事会第二十四次会议，审议通过了《关于公司参与设 立产业投资基金的议案》，同意公司与中传金控（天津）股权投资基金管理有限 公司及国瀚投资管理（北京）有限公司出资发起设立杭州传旭股权投资合伙企业 （有限合伙）（以下简称 "产业基金"或"基金"），主要投资处于创业期、成 长期的医药、大健康、生物医药等领域企业/项目。详见公司于 2022 年 6 月 3 日在 上海证券交易所网站（www.sse.com.cn）及指定信息披露媒体披露的《安旭生物关 于参与设立产业投资基金的公告》（公告编号：2022-032）。 基金名称：杭州传旭股权投资合伙企业（有限合伙） 基金类型：有限合伙企业 基金规模：10亿元人民币 执行事务合伙 ...

Market Overview - The Shanghai Composite Index closed at 3872.88 points, up 1.17%, with a total trading volume of 1.7438 trillion yuan [1] - As of the current date, 94 A-shares have surpassed their annual moving average [1] Stocks Surpassing Annual Moving Average - Notable stocks with significant deviation rates include: - Kaiwang Technology (301182) with a deviation rate of 15.21% and a daily increase of 17.68% [1] - Wanli Stone (002785) with a deviation rate of 9.52% and a daily increase of 10.01% [1] - Daqing Huake (000985) with a deviation rate of 9.44% and a daily increase of 10.00% [1] - Other stocks with smaller deviation rates include: - China CNR (601990) and Beidahuang (000995), both just above their annual moving average [1] Additional Stocks with Positive Performance - Other stocks showing positive performance include: - Tonghui Information (430090) with a daily increase of 6.20% and a deviation rate of 4.69% [1] - Huangtai Liquor (000995) with a daily increase of 5.17% and a deviation rate of 4.47% [1] - Nanjing Securities (601990) with a daily increase of 4.09% and a deviation rate of 4.00% [1]

Core Viewpoint - Anxu Bio experienced a slight increase in stock price and notable trading activity on September 25, 2023, with a focus on financing and stockholder data [1][2]. Group 1: Stock Performance and Trading Activity - On September 25, Anxu Bio's stock rose by 0.16%, with a trading volume of 17.95 million yuan [1]. - The financing buy-in amount for Anxu Bio on the same day was 4.54 million yuan, while the financing repayment was 2.36 million yuan, resulting in a net financing buy-in of 2.18 million yuan [1]. - As of September 25, the total financing and securities lending balance for Anxu Bio was 93.62 million yuan, which is 1.93% of its market capitalization and below the 50th percentile level over the past year, indicating a low financing balance [1]. Group 2: Securities Lending Activity - On September 25, Anxu Bio had no shares repaid or sold in securities lending, resulting in a sell amount of 0.00 yuan and a securities lending balance of 0.00 yuan, which is at a high level exceeding the 90th percentile over the past year [1]. Group 3: Financial Performance - For the first half of 2025, Anxu Bio reported a revenue of 230 million yuan, a year-on-year decrease of 7.42%, and a net profit attributable to shareholders of 59.31 million yuan, down 48.57% year-on-year [2]. - Since its A-share listing, Anxu Bio has distributed a total of 895 million yuan in dividends, with 657 million yuan distributed over the past three years [2]. Group 4: Shareholder Information - As of June 30, 2025, Anxu Bio had 6,024 shareholders, an increase of 1.50% from the previous period, with an average of 21,096 circulating shares per person, a decrease of 1.48% [2]. - Among the top ten circulating shareholders, Guangfa Value Core Mixed A held 3.01 million shares, unchanged from the previous period, while Zhaoshang Prosperity Preferred Stock A reduced its holdings by 10,000 shares to 600,000 shares [2].

Core Viewpoint - Anxu Bio has demonstrated resilience in the IVD industry by achieving a 24% increase in net profit excluding non-recurring items and a staggering 1420.52% increase in operating cash flow, despite the overall industry downturn in the first half of 2025 [1][2][3] Financial Performance - Initial impressions from Anxu Bio's half-year report show a revenue decline of 7.42% and a net profit drop of 48.57%, which can be misleading [2] - The decline in net profit is attributed to macroeconomic factors such as currency fluctuations and reduced government subsidies, rather than poor business performance [2] - The company's net profit excluding non-recurring items reached 23.5862 million yuan, reflecting a year-on-year increase of 24.85%, indicating strong core business performance [2] Cash Flow and Operational Efficiency - Anxu Bio reported a net operating cash flow of 3.52 million yuan, which is 15 times that of the same period last year, highlighting its ability to convert profits into cash effectively [3] - The increase in cash flow is due to improved accounts receivable turnover and better inventory management, showcasing the company's operational efficiency [3] R&D Investment and Certifications - Anxu Bio invested 20.64% of its revenue in R&D, significantly higher than the industry average of around 15%, focusing on long-term barriers rather than short-term products [4] - The company has obtained a total of 1,728 product certifications, with 148 new certifications in the first half of 2025, including 133 international certifications, establishing a strong competitive edge [4] Global Market Position - Anxu Bio's revenue is 90% derived from overseas markets, allowing it to avoid the price pressures associated with domestic centralized procurement [6] - The stability of orders from clients in Europe, Southeast Asia, and the established certification barriers contribute to the company's secure revenue base [6] Domestic Market Expansion - The company is accelerating its domestic market strategy, launching significant products such as the "Respiratory Virus Antigen Detection Pen" and "Chest Pain Triad Pen," targeting urgent clinical needs [7] - Anxu Bio is transitioning from an OEM to a self-branded model, with a current gross margin of 39%, which is expected to increase as its brand penetrates the market [7] New Business Opportunities - Anxu Bio is exploring new growth avenues in pet diagnostics and chronic disease management, with the global veterinary IVD market growing at 10.5% annually [8] - The introduction of the GluMate app for chronic disease management aims to create a closed-loop service model, integrating testing, data, and healthcare services [8][9] Strategic Outlook - Anxu Bio's strategy combines defensive measures, such as high overseas revenue and extensive certifications, with offensive initiatives in domestic markets and new business segments [10] - The company's shift from a product-centric to an ecosystem-oriented business model is expected to enhance its valuation and open new growth opportunities [10]